A Randomized Trial of Treatment Interruption before Optimized Antiretroviral Therapy for Persons with Drug‐Resistant HIV: 48‐Week Virologic Results of ACTG A5086 | Zendy

Constance A. Benson | Zendy; Florin Vaida | Zendy; Diane V. Havlir | Zendy; Gerald Downey | Zendy; Michael M. Lederman | Zendy; Roy M. Gulick | Zendy; Marshall J. Glesby | Zendy; Michael Wantman | Zendy; Christian Bixby | Zendy; Alex R. Rinehart | Zendy; Sally Snyder | Zendy; Rui Wang | Zendy; Sheran S. Patel | Zendy; John W. Mellors | Zendy

Open Access

A Randomized Trial of Treatment Interruption before Optimized Antiretroviral Therapy for Persons with Drug‐Resistant HIV: 48‐Week Virologic Results of ACTG A5086

Author(s) -

Constance A. Benson,

Florin Vaida,

Diane V. Havlir,

Gerald Downey,

Michael M. Lederman,

Roy M. Gulick,

Marshall J. Glesby,

Michael Wantman,

Christian Bixby,

Alex R. Rinehart,

Sally Snyder,

Rui Wang,

Sheran S. Patel,

John W. Mellors

Publication year - 2006

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1086/508289

Subject(s) - medicine , antiretroviral drug , antiretroviral therapy , human immunodeficiency virus (hiv) , drug , sida , drug holiday , drug resistance , lentivirus , pharmacotherapy , randomized controlled trial , viral load , hiv drug resistance , virology , viral disease , immunology , pharmacology , biology , microbiology and biotechnology

The role of structured treatment interruption (STI) before optimized antiretroviral therapy (ART) in patients with drug-resistant human immunodeficiency virus type 1 (HIV-1) is uncertain.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research